Pacific Biosciences of California (PACB) Projected to Post Quarterly Earnings on Thursday

Pacific Biosciences of California (NASDAQ:PACB) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Pacific Biosciences of California to post earnings of ($0.18) per share and revenue of $36.35 million for the quarter.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04. The firm had revenue of $37.15 million during the quarter, compared to analysts’ expectations of $36.90 million. Pacific Biosciences of California had a negative net margin of 430.93% and a negative return on equity of 52.07%. During the same quarter last year, the company posted ($0.26) earnings per share. On average, analysts expect Pacific Biosciences of California to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pacific Biosciences of California Stock Down 3.2%

Pacific Biosciences of California stock opened at $1.49 on Thursday. The company has a debt-to-equity ratio of 7.05, a current ratio of 6.68 and a quick ratio of 5.87. The company’s 50-day moving average is $1.30 and its 200-day moving average is $1.34. The firm has a market capitalization of $447.12 million, a PE ratio of -0.53 and a beta of 2.16. Pacific Biosciences of California has a fifty-two week low of $0.85 and a fifty-two week high of $2.72.

Analyst Ratings Changes

PACB has been the topic of several research analyst reports. Piper Sandler dropped their price objective on Pacific Biosciences of California from $2.00 to $1.25 and set a “neutral” rating on the stock in a research note on Thursday, May 15th. Stephens restated an “overweight” rating and issued a $1.80 price target on shares of Pacific Biosciences of California in a research note on Thursday, May 15th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $3.00 price objective on shares of Pacific Biosciences of California in a research report on Thursday, April 10th. Finally, Barclays decreased their price objective on shares of Pacific Biosciences of California from $2.00 to $1.50 and set an “equal weight” rating on the stock in a report on Wednesday, June 25th. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Pacific Biosciences of California currently has an average rating of “Hold” and an average price target of $2.06.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.